BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021
BridgeBio founder and CEO
BridgeBio will unveil new programs, share new information about its pipeline and discuss how it is broadening the scope of its R&D engine. It will also cover the company's most significant near-term catalysts with a focus on the upcoming topline results for acoramidis, BridgeBio's investigational therapy for transthyretin (TTR) amyloidosis (ATTR). ATTR is a rare heart condition with a progressive and debilitating impact on quality of life likely affecting more than 400,000 patients worldwide.
Topline results from Part A are expected in late 2021 and from Part B in 2023. The primary endpoint at Part A is the change from baseline in a 6-minute walk distance (6MWD) in trial participants receiving acoramidis or placebo after 12 months. If the change from baseline in 6MWD in Part A is highly statistically significant, BridgeBio expects to submit an application for regulatory approval of acoramidis in 2022 to the
The R&D Day program importantly and additionally will highlight BridgeBio's broader efforts in cardiorenal, progress in its KRAS portfolio, and advancements in its previously disclosed early-stage Mendelian programs. The Company will also be unveiling new programs in gene therapy.
- Welcome and introduction –
Grace Rauh, vice president of marketing and communications, BridgeBio Pharma
- Genetic basis of disease –
Richard Scheller, Ph.D., chairman of R&D, BridgeBio Pharma
- BridgeBio's endless summer –
Neil Kumar, Ph.D., founder and CEO, BridgeBio Pharma
- Precision cardiorenal introduction –
Cameron Turtle, D.Phil., chief strategy officer, BridgeBio Pharma
- Acoramidis: TTR stabilizer for ATTR –
Jonathan Fox, M.D., Ph.D., chief medical officer, BridgeBio Cardiorenal
- Encaleret: Calcium sensing receptor (CaSR) inhibitor for autosomal dominant hypocalcemia type 1 (ADH1) –
Mary Scott Roberts, M.D., senior director of clinical development, BridgeBio Cardiorenal
- Gene therapy platform –
Eric David, M.D., J.D., CEO, BridgeBio Gene Therapy
- Mendelian programs: Primary hyperoxaluria type 1 (PH1), limb-girdle muscular dystrophy type 2i (LGMD2i), recessive dystrophic epidermolysis bullosa (rDEB) –
Uma Sinha, Ph.D., chief scientific officer, BridgeBio Pharma
- Precision oncology programs: KRAS,
SHP2– Eli Wallace, Ph.D., chief scientific officer, BridgeBio Oncology
- BridgeBioX –
Charles Homcy, M.D., chairman of pharmaceuticals, BridgeBio Pharma
The event will be webcast, with a link available in the event calendar on BridgeBio's investor website, https://investor.bridgebio.com/. A replay of the webcast will be available for one year following the event.
To register for BridgeBio's R&D Day, please sign up here. To view the agenda and speaker profiles visit our R&D Day webpage. Attendees must register and watch the webcast to participate in the Q&A sessions.
BridgeBio Media Contact:
BridgeBio Investor Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021-301393685.html